Association between health-service use and multiplex genetic testing

Genetics in Medicine

Volumn 14, Issue 10, 2012, Pages 852-859

  Reid, Robert J ^a   McBride, Colleen M ^b   Alford, Sharon Hensley ^c   Price, Cristofer ^d   Baxevanis, Andreas D ^b   Brody, Lawrence C ^b   Larson, Eric B ^a  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d ABT ASSOCIATES   (United States)

Author keywords

delivery of health care; genetic counseling; genetic susceptibility; genetic testing

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEALTH SURVEY; HUMAN; LABORATORY TEST; MALE; PHYSICIAN;

ADULT; DATA COLLECTION; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEALTH SERVICES; HUMANS; OFFICE VISITS;

EID: 84867198371     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.52     Document Type: Article

References (36)

1. Evans JP, Dale DC, Fomous C. Preparing for a consumer-driven genomic age. N Engl J Med. 2010;363:1099-1103.
2. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet 2010;375:1525-1535.
3. Feero WG, Guttmacher AE, Collins FS. Genomic medicine-an updated primer. N Engl J Med 2010;362:2001-2011.
4. Annes JP, Giovanni MA, Murray MF. Risks of presymptomatic direct-toconsumer genetic testing. N Engl J Med 2010;363:1100-1101.
5. Kravitz RL, Bell RA, Azari R, Kelly-Reif S, Krupat E, Thom DH. Direct observation of requests for clinical services in office practice: what do patients want and do they get it? Arch Intern Med 2003;163:1673-1681.
6. Keitz SA, Stechuchak KM, Grambow SC, Koropchak CM, Tulsky JA. Behind closed doors: management of patient expectations in primary care practices. Arch Intern Med 2007;167:445-452.
7. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. CMAJ 2003;169:405-412.
8. McGuire AL, Diaz CM, Wang T, Hilsenbeck SG. Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth 2009;9:3-10.
9. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011;364:524-534.
10. McGuire AL, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 2008;300:2669-2671.
11. Caulfield T, Ries NM, Ray PN, Shuman C, Wilson B. Direct-to-consumer genetic testing: good, bad or benign? Clin Genet 2010;77:101-105.
12. McBride CM, Alford SH, Reid RJ, Larson EB, Baxevanis AD, Brody LC. Putting science over supposition in the arena of personalized genomics. Nat Genet 2008;40:939-942.
13. Wade CH, McBride CM, Kardia SL, Brody LC. Considerations for designing a prototype genetic test for use in translational research. Public Health Genomics 2010;13:155-165.
14. Hensley Alford S, McBride CM, Reid RJ, Larson EB, Baxevanis AD, Brody LC. Participation in genetic testing research varies by social group. Public Health Genomics 2011;14:85-93.
15. Budtz-Jørgensen E, Keiding N, Grandjean P, Weihe P. Confounder selection in environmental epidemiology: assessment of health effects of prenatal mercury exposure. Ann Epidemiol 2007;17:27-35.
16. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-936.
17. McBride CM, Alford SH, Reid RJ, Larson EB, Baxevanis AD, Brody LC. Characteristics of users of online personalized genomic risk assessments: implications for physician-patient interactions. Genet Med 2009;11: 582-587.
18. Udesky L. The ethics of direct-to-consumer genetic testing. Lancet 2010;376:1377-1378.
19. Feero WG, Guttmacher AE, Collins FS. The genome gets personal-almost. JAMA 2008;299:1351-1352.
20. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356-369.
21. Scheuner MT, Sieverding P, Shekelle PG. Delivery of genomic medicine for common chronic adult diseases: a systematic review. JAMA 2008;299: 1320-1334.
22. Song Y, Niu T, Manson JE, Kwiatkowski DJ, Liu S. Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. Am J Hum Genet 2004;74:208-222.
23. Florez JC, Sjögren M, Burtt N, et al. Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. Diabetes 2004;53: 3313-3318.
24. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26:76-80.
25. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006;38:320-323.
26. Mann V, Ralston SH. Meta-analysis of COL1A1 Sp1 polymorphism in relation to bone mineral density and osteoporotic fracture. Bone 2003;32: 711-717.
27. Ioannidis JP, Stavrou I, Trikalinos TA, et al. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res 2002;17:2048-2060.
28. Nordström A, Gerdhem P, Brändström H, et al. Interleukin-6 promoter polymorphism is associated with bone quality assessed by calcaneus ultrasound and previous fractures in a cohort of 75-year-old women. Osteoporos Int 2004;15:820-826.
29. Boekholdt SM, Peters RJ, Fountoulaki K, Kastelein JJ, Sijbrands EJ. Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. Hum Genet 2003;113:417-425.
30. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 2005;111:278-287.
31. Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004;109:1359-1365.
32. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, van Duijn CM. The-514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. J Clin Endocrinol Metab 2004;89:3858-3863.
33. Mondry A, Loh M, Liu P, Zhu AL, Nagel M. Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: surprising new findings and meta-analysis of data. BMC Nephrol 2005;6:1.
34. Feyler A, Voho A, Bouchardy C, et al. Point: myeloperoxidase-463G-> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:1550-1554.
35. Kim DH, Ahn YO, Lee BH, Tsuji E, Kiyohara C, Kono S. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. Cancer Lett 2004;216:199-205.
36. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000;66: 176-186.